Evidence map›Paper›PMID 35369356›Full record

ArticleFrontiers in cardiovascular medicine2022

Valosin Containing Protein as a Specific Biomarker for Predicting the Development of Acute Coronary Syndrome and Its Complication.

Chenchao Xu, Bokang Yu, Xin Zhao, Xinyi Lin, Xinru Tang, Zheng Liu, Pan Gao, Junbo Ge, Shouyu Wang, Liliang Li

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Chenchao XuDepartment of Forensic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Bokang YuDepartment of Forensic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Xin ZhaoDepartment of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
Xinyi LinDepartment of Forensic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Xinru TangDepartment of Forensic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Zheng LiuDepartment of Forensic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Pan GaoDepartment of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
Junbo GeDepartment of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
Shouyu WangDepartment of Forensic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Liliang LiDepartment of Forensic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Shanghai Medical College of Fudan University · CNZhongshan Hospital · CNThe First Affiliated Hospital, Sun Yat-sen University · CN

Funding

Medical Research Council MC_PC_17228Medical Research Council MC_QA137853
6 · The paper itself

Abstract

Background: Acute coronary syndrome (ACS) consists of a range of acute myocardial ischemia-related manifestations. The adverse events of ACS are usually associated with ventricular dysfunction (VD), which could finally develop to heart failure. Currently, there is no satisfactory indicator that could specifically predict the development of ACS and its prognosis. Valosin-containing protein (VCP) has recently been proposed to protect against cardiac diseases. Hence, we aimed to assess whether VCP in serum can serve as a valuable biomarker for predicting ACS and its complication. Methods: Human serum samples from 291 participants were collected and classified into four groups based on their clinical diagnosis, namely healthy control ( Results: Serum VCP levels were significantly higher in the ACS group compared with the rest groups. Besides, the VCP levels of patients with ACS with VD were significantly lower compared to those without VD. Multivariate logistic regression analysis revealed that VCP was associated with both the risk of ACS ( Conclusion: Valosin-containing protein could act as a stable biomarker in predicting the development of ACS and its complication VD.

Indexed as

acute coronary syndromeprognosis predictionserological biomarkervalosin-containing proteinventricular dysfunction

Identifiers

PMID35369356
PMCPMC8971847
OpenAlexW4220760332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.